§ 357.850. Labeling of deodorant drug products for internal use.
394 words·~2 min read·
/us/cfr/t21/s§ 357.850·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
(a)Statement of identity. The labeling of the product contains the established name of the drug, if any, and identifies the product as a “deodorant for internal use” or as a “colostomy or ileostomy deodorant.”
(b)Indications. The labeling of the product states, under the heading “Indications,” any of the phrases listed in paragraph
(b)of this section as appropriate. Other truthful and nonmisleading statements, describing only the indications for use that have been established and listed in paragraph
(b)of this section may also be used, as provided in § 330.1(c)(2) of this chapter, subject to the provisions of section 502 of the Federal Food, Drug, and Cosmetic Act (the act) relating to misbranding and the prohibition in section 301(d) of the act against the introduction or delivery for introduction into interstate commerce of unapproved new drugs in violation of section 505(a) of the act.
(1)For products containing bismuth subgallate identified in § 357.810(a). “An aid to reduce odor from a colostomy or ileostomy.”
(2)For products containing chlorophyllin copper complex identified in § 357.810(b).
(i)“An aid to reduce odor from a colostomy or ileostomy.”
(ii)“An aid to reduce fecal odor due to incontinence.”
(c)Warnings. The labeling of the product contains the following warnings under the heading “Warnings”:
(1)For products containing chlorophyllin copper complex identified in § 357.810(b).
(i)“If cramps or diarrhea occurs, reduce the dosage. If symptoms persist, consult your doctor.”
(ii)The warning required by § 330.1(g) of this chapter concerning overdose is not required on products containing chlorophyllin copper complex identified in § 357.810(b).
(2)[Reserved]
(d)Directions. The labeling of the product contains the following information under the heading “Directions.”
(1)For products containing bismuth subgallate identified in § 357.810(a). Adults and children 12 years of age and over: Oral dosage is 200 to 400 milligrams up to 4 times daily. Children under 12 years of age: consult a doctor.
(2)For products containing chlorophyllin copper complex identified in § 357.810(b). Adults and children 12 years of age and over: Oral dosage is 100 to 200 milligrams daily in divided doses as required. If odor is not controlled, take up to an additional 100 milligrams daily in divided doses as required. The smallest effective dose should be used. Do not exceed 300 milligrams daily. Children under 12 years of age: consult a doctor.
Connections1 cite this
Cited by 1 section
register
Citation graph
cites case law
§ 357.850
Labeling of deodorant drug products for internal use.
Fed. Reg.×1
Cites 0Cited by 1 across 1 source